Heart disease is the major cause of death across the globe. According to the World Health Organization, around 17.9 million people died from cardiovascular diseases (CVDs) in 2016, which accounted for 31% of all global deaths. 85% of these deaths are caused due to heart disease and stroke. Coronary heart disease, also called ischemic heart disease, is the most common heart problem around the world. In the past decade, significant changes in the diagnosis and surgeries of coronary artery diseases (CADs) and myocardial ischemia are undergoing major technological advancements. As a result, the global myocardial ischemia market was rising and attained a value of 37.5 billion in 2018. Furthermore, the demand for this market is accelerating at a CAGR of 6% during the forecast period 2019-2025.

The Prominence of Research Activities in the Global Myocardial Ischemia Market

In the modern era of revascularization, major advancements are observed in the management and effective care of myocardial ischemia or cardiac ischemia and coronary artery diseases. With the improved treatment techniques, the severity and predominance of myocardial ischemia and anginal symptoms are reducing further. Coronary angiography, a standard diagnosis method of cardiac ischemia, is undergoing major research activities and clinical trials in the invasive coronary angiography and non-invasive coronary angiography techniques. Furthermore, the research activities related to these diagnosis techniques are focusing on the effective outcomes and long-term predictability of disease based on the patient’s condition.

Recently, in 2018, a research supported by the Radiological Society of North America showed that cardiac hybrid imaging combined with coronary computed tomography (CT) angiography is an effective long-term predictor of adverse cardiac events. In this research, the patients underwent hybrid imaging with myocardial perfusion with SPECT (single photon emission tomography) and coronary CT angiography (CCTA). The findings with different levels of ischemia evidence are noted. These results are used to predict adverse cardiac events in patients with CAD. This shows that cardiac hybrid imaging is an excellent long-term predictor to make treatment decisions related to revascularization procedure, which include bypass or angioplasty. The activity is yet to proceed with the clinical trial. Furthermore, the scope of the diagnostics services in identifying myocardial ischemia and other heart conditions which uses perfusion imaging and hybrid imaging as well as ‘triple hybrid imaging’ that combines SPECT or CCTA hybrid with coronary artery shear stress information, are growing in the global myocardial ischemia market.

North America Domineering in the Global Myocardial Ischemia Market

North America is the dominant region in the global myocardial ischemia market and accounted for a share of 32% in 2018. High prevalence of heart diseases in the countries such as the U.S and Canada are the major drivers constituting to the dominance of the myocardial ischemia market in North America. For decades now, heart disease is the leading cause of death in the U.S., according to the Centers for Disease Control and Prevention (CDC). Every 40 seconds, an American is projected to have a heart attack. Cardiac ischemia when it lasts for a long duration or with high-severity results in myocardial infarction or heart attacks. Diabetes is one of the leading causes of myocardial infarction in the U.S. In 2013-2016, about 9.8% of American adults have diagnosed diabetes while 3.7% of them had undiagnosed diabetes according to the American Heart Association (AHA). A huge population with diabetes, overweight, physically inactive, and obese cases further contribute to the growth of cardiac ischemia. Besides, the AHA projects, by 2035, nearly half i.e., around 45% of the American population are estimated to suffer from some cardiovascular disease and the associated medical costs and indirect costs will skyrocket to $1.1 trillion. Therefore, the National Institutes of Health (NIH) and the CDC are experiencing significant investments to reduce the rising tide of CVD. As a result, prevention and control methods of ischemia, angina pectoris, and other heart diseases are increasing in the United States.

In Canada, heart disease is the second leading cause of death for the past few decades, despite significant advancements occurring in disease management, treatment, and public health interventions. Though the death rates reduced continuously since 1969, the prevalence of the disease still exists in this country. To prevent this, the government of Canada is investing in programs such as Kid Food Nation, Healthy Eating Strategy, Break it Off, Run to Quit, Don’t Change Much, and APPLE Schools. These programs are promoting to quit smoking, to learn healthy eating habits and become more active physically among its citizens. Furthermore, research and initiatives such as the Heart and Stroke Foundation’s Advancing Women’s Heart Health are rising in Canada. Owing to these high incidences and investments in the U.S and Canada, the myocardial ischemia market is surging in North America.

Hospitals and Clinics Playing Key Role in the Myocardial Ischemia Market

Hospitals and Clinics constitute the leading segment in the global myocardial ischemia market, and the segment is projected to rise at a CAGR of 7.5% during the forecast period. Both diagnosis and treatment services are boosting the myocardial ischemia market growth, which is majorly carried out by the hospitals and clinics. Advancements, while presenting symptoms and assessing risk factors in the disease related to the patient’s condition, are identified in the hospitals. In clinics and hospitals, cardiologists review drugs related to ischemia treatment and carry out research activities under the guidance of government and other healthcare associations.

Moreover, governments of respective countries collaborate with major hospitals and healthcare systems to address the disparities of CVD and ischemic heart diseases. As part of the collaboration, the programs funded and initiated improve the clinical and functional outcomes of the myocardial ischemia and myocardial infarction patients. Also, recently, a research activity carried by Rutgers University concluded that hospital performance scores play a substantial role in the treatment of heart attacks. The researchers found that there is a greater risk of early death or another heart attack for the patients treated in hospitals with low scores. Therefore, the significance of hospitals and clinics is quite impactful in the myocardial ischemia market. 

Key Companies in the Myocardial Ischemia Market

The core companies operating with a major share in the global myocardial ischemia market are AstraZeneca plc, Taxus Cardium Pharmaceuticals, Novartis AG, Daiichi Sankyo Company Limited, ViroMed Co. Ltd., Bayer AG, Boehringer Ingelheim group, International GmbH, Boston Scientific Corporation, and Baxter International Inc. These key players are carrying out ceaseless clinical trials and drug releases, which are thriving in this market. For instance, in 2016, Daiichi Sankyo Company, Limited launched antiplatelet agent Efient® Tablets 20mg. After the completion of 3 clinical trials, this drug is used to reduce the incidence of ischemic events in patients with ischemic heart disease.

Talk to one of our sales representative about the full report by providing your details in the link below:


Related Reports:

 A. Myocardial Infarction Treatment Market


B. Cardiac Implant Devices Market


Any other custom requirements can be discussed with our team, drop an e-mail to [email protected] to discuss more about our consulting services.

Media Contact:

Mr. Venkat Reddy

Sales Manager          

Email: [email protected]

Contact Sales: +1-614-588-8538 (Ext-101)

About IndustryARC: IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.